NOVEMBER 2016, JOURNÈE DE FORMATION CONTINUE DE LA SWISS SCC

2 Novembre 2016,  Lausanne

VITROSCREEN: IN VITRO SCIENCE AND NOT ONLY IN VITRO TEST

VitroScreen participated to the Swiss SCC event as sponsor because strongly believes that cosmetic claims can be substantiated, better understood and presented by using alternatives to conventional 2D cell culture and humans.

3D human skin models represent the new millenium reference in life sciences and their wide use will change the way to model, refine and support cosmetics efficacy and safety assessment by:

  • being complementary to in vivo evaluation;
  • adding value to direct and indirect consumer communication with deeper, stronger and more robust evidence of product efficacy corroborated by histological images;
  • being a unique and essential tool and not just an alternative, providing the mechanism of action and strong scientific evidences that cannot be obtained with in vivo approaches, either for practical or ethical reasons;
  • developing tools for formulators providing proof of concept for actives or prototype formulations, supporting technical scientific dossiers compliant to Regulation EC n. 1223/2009;
  • performing screening and comparing products with reproducible results during the development;
  • Quality Assurance principles are applied by VitroScreen throughout each study and research project, guaranteeing secured information management and providing the customer with in-depth reporting documents

VitroScreen does not simply deliver a test, but a completely new and different approach leading to a strong body of evidences. Being a flexible, reactive and pro-active partner open to innovation challenges, VitroScreen supports the customer’s management teams in formulation, Research & Development, marketing and communication, offering a unique expertise in the use of 3D human reconstructed tissue models for safety and efficacy testing within the cosmetic and pharmaceutical industries. A robust body of evidences and not only the result of single test for safety assessment is generated by performing the Multiple Endpoint Approach (MEA), leading to the new safety concept, the bio-compatibility, based on more robust information about product’s biological properties.

2020-09-02T18:40:34+00:00